ABCELLERA BIOLOGICS
AbCellera focuses on therapeutic antibodies, screening, choosing, and analyzing millions of naturally produced antibodies to be used as next-generation drug candidates. It specializes in the fields of biotechnology, medicine, and therapeutics.
ABCELLERA BIOLOGICS
Industry:
Biotechnology Medical Therapeutics
Founded:
2012-01-01
Status:
Active
Contact:
(604) 559-9005
Total Funding:
371.22 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default LetsEncrypt Nginx Amazon IPv6 Google Apps For Business Microsoft Azure DNS
Similar Organizations
Rakuten Medical
Rakuten Medical is a Bio-technology Company.
Enliven Therapeutics
Enliven Therapeutics is a precision oncology company developing small molecule therapies to extend and improve patient lives.
Proteostasis Therapeutics
Proteostasis Therapeutics is a clinical stage biopharmaceutical company developing small molecule therapeutics to treat cystic fibrosis.
Current Advisors List
Board_member
Current Employees Featured
Kevin Heyries Co-Founder, Head of Business Development @ AbCellera Biologics
Co-Founder, Head of Business Development
2017-01-01
Carl Hansen CEO @ AbCellera Biologics
CEO
Véronique Lecault Co-Founder @ AbCellera Biologics
Co-Founder
2012-12-01
Jake Beverage Vice President, Alliance Management @ AbCellera Biologics
Vice President, Alliance Management
2021-11-01
Véronique Lecault Chief Operating Officer @ AbCellera Biologics
Chief Operating Officer
2019-09-01
Véronique Lecault Corporate Development @ AbCellera Biologics
Corporate Development
2017-01-01
Anne Stevens Head of Business Partnering @ AbCellera Biologics
Head of Business Partnering
2020-11-01
Bryan Barnhart Scientific Director @ AbCellera Biologics
Scientific Director
2020-01-01
Neil Berkley Chief Business Officer @ AbCellera Biologics
Chief Business Officer
2021-07-01
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2021-09-13 | Tetragenetics | Tetragenetics acquired by AbCellera Biologics | N/A |
| 2020-11-18 | Trianni | Trianni acquired by AbCellera Biologics | 90 M USD |
| 2020-08-20 | Dualogics - OrthoMab | Dualogics - OrthoMab acquired by AbCellera Biologics | N/A |
| 2018-08-01 | Lineage Biosciences | Lineage Biosciences acquired by AbCellera Biologics | N/A |
Investors List
Eli Lilly
Eli Lilly investment in Series B - AbCellera Biologics
Presight Capital
Presight Capital investment in Series B - AbCellera Biologics
Founders Fund
Founders Fund investment in Series B - AbCellera Biologics
OrbiMed
OrbiMed investment in Series B - AbCellera Biologics
DCVC
DCVC investment in Series B - AbCellera Biologics
Peter Thiel
Peter Thiel investment in Series B - AbCellera Biologics
Viking Global Investors
Viking Global Investors investment in Series B - AbCellera Biologics
University of Minnesota
University of Minnesota investment in Series B - AbCellera Biologics
Government of Canada
Government of Canada investment in Grant - AbCellera Biologics
Founders Fund
Founders Fund investment in Series A - AbCellera Biologics
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2020-09-30 | Invetx | AbCellera Biologics investment in Series A - Invetx | 10.25 M USD |
| 2020-02-24 | Invetx | AbCellera Biologics investment in Series A - Invetx | 15 M USD |
Key Employee Changes
| Date | New article |
|---|---|
| 2021-07-13 | AbCellera Appoints Neil Berkley as Chief Business Officer |
More informations about "AbCellera Biologics"
Team - AbCellera
AbCellera grew out of the idea that single-cell microfluidics and next-generation technologies can radically change how we discover and develop new medicines. But this isn’t just about having …See details»
AbCellera - Wikipedia
AbCellera Biologics Inc. is a Vancouver, British Columbia-based contract research organization (CRO) that is contracted by biotechnology and pharmaceutical companies for antibody …See details»
AbCellera Biologics Inc. - AbCellera Launches Second Phase of …
Sep 21, 2022 AbCellera (Nasdaq: ABCL) today announced it has launched the second phase of its global headquarters expansion by breaking ground on its new facility in Vancouver, …See details»
AbCellera Biologics Inc. - AbCellera Closes $105 Million Series B ...
May 27, 2020 AbCellera provides pharma and biotech partners with an AI-powered, full-stack drug discovery platform to accelerate development of biologics VANCOUVER, British …See details»
AbCellera Biologics Inc. - AbCellera Partners with the …
May 24, 2023 About AbCellera Biologics Inc. AbCellera is breaking the barriers of conventional antibody drug discovery to bring better medicines to patients, sooner. AbCellera’s engine integrates expert teams, technology, and facilities …See details»
Partners - AbCellera
Strategic Partnerships Making medicines together. We strategically partner with groups that have novel science and innovative technology to develop antibody-based medicines. Our Impact Making a difference for patients. Since 2015, we …See details»
AbCellera Biologics Inc. - AbCellera Reports Full Year 2024 …
Dec 31, 2023 AbCellera (Nasdaq: ABCL) today announced financial results for the full year 2024. All financial information in this press release is reported in U.S. dollars, unless otherwise …See details»
AbCellera - Crunchbase Investor Profile & Investments
AbCellera is an antibody discovery and development engine that’s specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic – and …See details»
AbCellera Biologics Inc. - Investor Relations
Feb 11, 2025 AbCellera’s engine integrates technology, data science, infrastructure, and interdisciplinary teams to solve the most challenging antibody discovery problems. AbCellera …See details»
AbCellera Biologics Inc. - AbCellera and Lilly Expand Collaboration …
Jul 31, 2024 AbCellera (Nasdaq: ABCL) announced today that it has expanded its existing collaboration with Eli Lilly and Company (Lilly) to discover therapeutic antibodies for programs …See details»
Member profile: AbCellera Biologics Inc. | BIA - BioIndustry
About AbCellera Biologics Inc. AbCellera is breaking the barriers of conventional antibody drug discovery to bring better medicines to patients, sooner. AbCellera’s engine integrates expert …See details»
AbCellera Biologics Inc. - AbCellera to Collaborate with Biogen to ...
Mar 11, 2024 AbCellera (Nasdaq: ABCL) and Biogen Inc. (Nasdaq: BIIB) have entered into a strategic collaboration to discover antibodies for a novel target that enables the delivery of …See details»
AbCellera Biologics Inc. - AbCellera Continues Expansion and ...
Jun 22, 2021 AbCellera has also discovered a second antibody, LY-CoV1404, that is being advanced by Eli Lilly & Company to address emerging and future variants. This antibody has …See details»
Canada and British Columbia invest in AbCellera’s state-of-the-art ...
May 24, 2023 AbCellera is a Canadian technology company that is breaking the barriers of conventional antibody drug discovery to bring better medicines to patients, sooner. AbCellera’s …See details»
AbCellera - Funding, Financials, Valuation & Investors - Crunchbase
AbCellera is registered under the ticker NASDAQ:ABCL . Their stock opened with $20.00 in its Dec 10, 2020 IPO. Stock Symbol NASDAQ:ABCL ; Valuation at IPO $5.3B; Money Raised at …See details»
AbCellera Biologics: Unraveling its Core Product Projections and ...
Oct 28, 2023 AbCellera Biologics exemplifies the convergence of biotechnology and artificial intelligence. As the company forges ahead, its groundbreaking platforms and methodologies …See details»
Platforms - AbCellera
Our Technologies Unlocking antibody drug targets, classes, and modalities. Our Platforms Expanding the reach of antibody therapeutics. We have developed technology platforms to …See details»
The Innovators: AbCellera Biologics found its moment to shine …
Feb 2, 2021 When COVID-19 struck, AbCellera Biologics was better prepared than most. Since 2018, through a contract with the Pandemic Prevention Platform (P3) program run by the U.S. …See details»
AbCellera Biologics Inc. - AbCellera Announces Presentation of In …
Mar 25, 2025 AbCellera (Nasdaq: ABCL) today announced an upcoming poster presentation that includes preclinical in vivo data on its PSMA x CD3 T-cell engagers at the American …See details»
AbCellera to Participate at Upcoming Investor Conferences in May …
Apr 8, 2025 Goldman Sachs 46th Annual Global Healthcare conference, June 9-11 Visit AbCellera's Investor Relations website for additional information. About AbCellera Biologics …See details»